The new chair of Germany’s most powerful health body has said something nobody in that chair has said before. She also named, quite precisely, what it would cost.
Sonja Optendrenk has led the Gemeinsamer Bundesausschuss (G-BA) since early July 2026. The G-BA is the joint self-governing body that decides which treatments the statutory health insurers reimburse for 74 million insured people in Germany. In early August she told the news magazine Der Spiegel that it would be worth considering recognising weight-loss drugs as a reimbursable benefit under certain conditions. In her words, as reproduced by the dts news agency and by Tagesspiegel: Germany is having “a backward discussion about obesity”. Other countries, she said, notably the United Kingdom, have “consistently accepted that this is a real illness that cannot be reversed by sport and better nutrition alone”.
This is a proposal, not a decision. But it comes from the office that would have to write the details, and it is more specific than such proposals usually are.
What the statute actually says
The reason Wegovy and Mounjaro are paid for out of pocket in Germany sits in section 34, paragraph 1 of the Fifth Social Code. It excludes medicines whose use primarily serves “an increase in quality of life”. Then comes a list worth reading in full. Excluded in particular are medicines predominantly used:
- to treat erectile dysfunction
- to stimulate or increase sexual potency
- for smoking cessation
- for slimming or appetite suppression
- to regulate body weight
- to improve hair growth
That is the company fat bodies keep in German social law: filed between potency drugs and hair growth. Not as an accident of drafting, but as the law in force.
Optendrenk points at exactly that. The fact that drugs explicitly licensed to treat obesity fall under this paragraph is, for the people affected, “a sign that this recognition is missing”.
It is the most honest description of the problem to come from that direction so far. The issue is not only money. It is which list a body gets sorted into.
The precedent is sitting in the same section
What separates this from a statement of intent is that the template already exists one paragraph down.
For smoking cessation, the legislature has already broken its own rule. Section 34, paragraph 2 gives insured people with a diagnosed severe tobacco dependence a claim to a one-time supply of cessation medication, but only within evidence-based programmes. A repeat supply is possible no earlier than three years after the first course ends. And the specifics, which drugs under which conditions, are set by the G-BA in its own guidelines.
So smoking cessation remains on the exclusion list in paragraph 1 and still has a narrow, conditional claim in paragraph 2. The legislature cuts the exception, the committee fills it in.
That is precisely the mechanism Optendrenk floated: the legislature could instruct the G-BA to determine which patient groups should receive the drugs, for how long, and with what accompanying measures. Anyone wanting to know what that looks like in practice does not have to speculate. The tobacco rule is the blueprint: a certified severity, a programme around it, a waiting period.
The price is written into the same sentence
This is where it gets complicated for fat people rather than simply good.
In Optendrenk’s own argument, the route to coverage runs through recognition as a disease. The UK, she says, accepted that this is a real illness. Access follows once the body counts as requiring treatment.
That is the same logic German guideline medicine runs on. The national obesity guideline added a dedicated chapter on stigmatisation in 2024, and that chapter closes by arguing that recognising obesity as a disease implies making billable treatment available nationwide. Destigmatisation as the argument for more treatment. We set out the fault line in our guide to what Health at Every Size actually means: one framework says care should not have to be earned, the other says care arrives once the body carries a diagnosis.
Both beat the status quo, in which fat people are neither recognised nor treated. But they are two different futures. In one you get care because you are a person. In the other you get it because you are a case.
Her own caveat is the most interesting part
Optendrenk limited her own proposal, and more sharply than the headlines suggest: “As long as the weight comes straight back after stopping, an injection alone is not a model of care.” Long-term studies, she noted, are missing.
That sentence can be read two ways, and both readings will be used in the coming months.
Read weight-neutrally, it says: a drug whose effect ends when you stop taking it is no substitute for care that takes fat people seriously. That matches what the research already shows, and it argues against the idea that a prescription settles the matter.
Read from the industry side, the same sentence says: if the weight comes back after stopping, then nobody should stop. A time-limited treatment becomes permanent medication, and a line item becomes a subscription. Anyone who has followed the American coverage fights knows this argument. We traced the access question across countries in France pays, Germany does not and the class dimension in the GLP-1 access gap.
Which reading wins will not be decided by her sentence. It will be decided by whoever gets to define the accompanying measures she mentioned.
What it means in practice
In the short term, nothing. There is no decision, no instruction from the legislature and no timetable. Anyone who wants a prescription today still pays for it themselves.
Over the medium term, three things are worth watching, because they decide whether a change creates access or builds a new hurdle.
The eligibility criteria. Following the tobacco model, some certified severity will be required. For weight that almost certainly means BMI thresholds. Anyone just below falls out, and the line is always arbitrary.
The accompanying measures. Mandatory programmes can mean good care, or they can mean a compliance test in which reimbursement is tied to demonstrated good behaviour. The difference lives in the detail, and the detail will not be in the statute. It will be in a guideline.
The side effect on everything else. Coverage coupled to disease recognition reinforces the picture of the fat body as a case for treatment. In the very same practice where it opens access to one drug, it can narrow access to everything else. What that looks like in the room is in our guide to what to do when a doctor blames everything on your weight.
What we are not doing here
We are not recommending weight-loss drugs and we are not warning anyone off them. That is a medical decision between you and a practice that takes you seriously.
The point is a different one. A country that files fat bodies next to hair-growth products in its statute book is, for the first time, hearing from the top of its own health self-government that the sentence might be wrong. That is good news. It just arrives with an invoice, and the invoice reads: diagnosis.
The cost argument is already being staged, incidentally. Tagesspiegel puts the direct medical costs of obesity and its sequelae in Germany at roughly 29 billion euros a year, citing current calculations without naming them. We report the figure as what it is: a number circulating in the debate whose source we have not checked against the original. Why that is a recurring problem with numbers about fat people is the longer story in who pays for weight stigma research.
Fatosphere holds one red line: we do not promote diet or weight-loss products, and we do not publish before-and-after logic. This piece reports a health policy debate without recommending any treatment.
Sources
- Sonja Optendrenk interviewed by Der Spiegel, reproduced by the dts news agency (Presse Augsburg, 2 August 2026) and by Tagesspiegel (2 August 2026). The interview itself is paywalled; the quoted sentences match across both reproductions.
- Section 34 of the German Social Code Book V, paragraph 1 (exclusion of medicines primarily serving an increase in quality of life) and paragraph 2 (claim in cases of severe tobacco dependence), read on 5 August 2026 at gesetze-im-internet.de.
- Deutsche Adipositas-Gesellschaft (lead), S3 guideline Prävention und Therapie der Adipositas, AWMF register number 050-001, version 5.0, 7 October 2024, chapter 2 on stigmatisation.
Image credit: cover graphic by Fatosphere, generated programmatically. Not a photograph and not a depiction of real people.